Citations

Clear

1575 citation(s) found for "Im, Gene".

Transcript-Activated Coatings on Titanium Mediate Cellular Osteogenesis for Enhanced Osteointegration
Fayed, Omnia, Griensven, Martijn van , Birgani, Zeinab Tahmasebi , Balmayor, Elizabeth R. , van Griensven, Martijn , Balmayor, Elizabeth R , Plank, Christian

Mayo Clinic

Molecular Pharmaceutics | January 25, 2021 | Volume: 18 | Issue: 3 | Pages: 1121-1137

10.1021/acs.molpharmaceut.0c01042 | PMID 33492959 Get It

Duodenal mucosal mitochondrial gene expression is associated with delayed gastric emptying in diabetic gastroenteropathy
Narayanan, Susrutha Puthanmadhom, O’Brien, Daniel R. , Sharma, Mayank , Miller, Karl N. , Adams, Peter D. , Passos, João F. , Eirin, Alfonso , Ördög, Tamás , Bharucha, Adil E. , Puthanmadhom Narayanan, Susrutha, Passos, João F , Eirin, Alfonso , Adams, Peter

Mayo Clinic

JCI Insight | January 24, 2021 | Volume: 6 | Issue: 2 | Pages: No page available

10.1172/jci.insight.143596 | PMID 33491664 Get It

Hindered by a limited understanding of the mechanisms responsible for diabetic gastroenteropathy (DGE), management is symptomatic. We investigated the duodenal mucosal expression of protein-coding genes and microRNAs (miRNA) in DGE and related them to clinical features. The diabetic phenotype, gastric emptying, mRNA, and miRNA expression and ultrastructure of duodenal mucosal biopsies were compared in 39 DGE patients and 21 controls. Among 3175 differentially expressed genes (FDR < 0.05), several mitochondrial DNA–encoded (mtDNA-encoded) genes (12 of 13 protein coding genes involved in oxidative phosphorylation [OXPHOS], both rRNAs and 9 of 22 transfer RNAs) were downregulated; conversely, nuclear DNA–encoded (nDNA-encoded) mitochondrial genes (OXPHOS) were upregulated in DGE. The promoters of differentially expressed genes were enriched in motifs for transcription factors (e.g., NRF1), which regulate mitochondrial biogenesis. Seventeen of 30 differentially expressed miRNAs targeted differentially expressed mitochondrial genes. Mitochondrial density was reduced and correlated with expression of 9 mtDNA OXPHOS genes. Uncovered by principal component (PC) analysis of 70 OXPHOS genes, PC1 was associated with neuropathy ( P = 0.01) and delayed gastric emptying ( P < 0.05). In DGE, mtDNA- and nDNA-encoded mitochondrial genes are reduced and increased — associated with reduced mitochondrial density, neuropathy, and delayed gastric emptying — and correlated with cognate miRNAs. These findings suggest that mitochondrial disturbances may contribute to delayed gastric emptying in DGE.
PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
Cercek, Andrea , Ng, Kimmie , Sanchez, Federico Augusto, Bruggeman, Sarah, Larson, Joseph J. , Finley, Gene Grant, Lenz, Heinz‐Josef , Corcoran, Ryan B. , Strickler, John H. , Ou, Fang‐Shu , Bekaii‐Saab, Tanios , Parseghian, Christine Megerdichian , Hubbard, Joleen M. , Wu, Christina , Kopetz, Scott

Mayo Clinic

Journal of Clinical Oncology | January 22, 2021 | Volume: 39 | Issue: 3_suppl | Pages: TPS143-TPS143

10.1200/jco.2021.39.3_suppl.tps143 Get It

TPS143 Background: Patients with KRAS and NRAS ( RAS) wild-type mCRC benefit from the epidermal growth factor receptor (EGFR) monoclonal antibodies (Abs) panitumumab and cetuximab, but nearly all patients experience resistance. Blood-based profiling of cell free DNA (cfDNA) can identify genomic alterations that drive acquired EGFR Ab resistance. After discontinuation of anti-EGFR Abs, acquired genomic alterations decay over time to undetectable levels. Some studies have suggested clinical benefit from EGFR Ab rechallenge, but there is limited evidence that EGFR Ab rechallenge improves survival compared to standard of care (SOC) therapies. We hypothesize that cfDNA profiling will identify patients appropriate for panitumumab rechallenge, and that these molecularly selected patients will have improved survival compared to current SOC therapies. Methods: This is a randomized phase II, open label study designed to compare the overall survival (OS) of panitumumab rechallenge versus SOC (investigator choice TAS-102 or regorafenib). Secondary objectives include comparisons of progression free survival, objective response rate, clinical benefit rate, and quality of life as measured by the linear analogue self-assessment (LASA) questionnaire. Eligible patients have radiographically measurable KRAS, NRAS, and BRAF codon 600 wild-type mCRC based on tumor tissue testing, and must have experienced progression or intolerance to treatment with a fluoropyrimidine, oxaliplatin, irinotecan, an anti-VEGF Ab, and an anti-PD-1 Ab if the tumor has mismatch repair deficiency or is MSI-H. Progression after at least 4 months treatment with an anti-EGFR Ab is required. All patients must be enrolled in the COLOMATE cfDNA screening protocol (NCT03765736) and meet molecular eligibility based on Guardant360 cfDNA profiling (absence of amplification of ERBB2, KRAS, NRAS, and MET; absence of mutations of BRAF, EGFR, ERBB2, KRAS, NRAS, and MET [mutant allele frequency > 0.5%]). Greater than 90 days must have elapsed between the most recent treatment with an anti-EGFR Ab and cfDNA profiling. Dosing for all study drugs is according to clinical SOC. 120 patients will be randomized 1:1 to panitumumab rechallenge or SOC. With 83 OS events, this study will have 80% power to detect an improvement in median OS from 6.5 to 10 months (HR=0.65; 1-sided α= 0.15). This study began enrollment in 6/2020. Recruitment is ongoing at 16 sites in the Academic and Community Cancer Research United (ACCRU) network (ACCRU-GI-1623). Clinical trial information: NCT03992456.
Pseudomyogenic hemangioendothelioma of bone with rare WWTR1‐FOSB fusion gene: Case report and literature review
Murshed, Khaled , Torres‐Mora, Jorge , Elsayed, Ahmed Mounir, Ammar, Adham , Al‐Bozom, Issam , Murshed, Khaled A

Mayo Clinic

Clinical Case Reports | January 19, 2021 | Volume: 9 | Issue: 3 | Pages: 1494-1499

10.1002/ccr3.3808 | PMID 33768875 Get It

AbstractPseudomyogenic hemangioendothelioma rarely arises in bone. WWTR1‐FOSB fusion gene is rarely reported in PMHE of bone. Currently, fusion genes can be used as diagnostic markers in PMHE; however, their prognostic and therapeutic significance is unclear.
Author response: MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor–1
Codreanu, Simona G. , Thomas, Lance R. , Lorey, Shelly L. , Machida, Yuichi , Popay, Tessa M. , Wang, Jing , Adams, Clare M. , Howard, Gregory C. , Sherrod, Stacy D. , McLean, John A. , Weissmiller, April M. , Eischen, Christine M. , Liu, Qi , Tansey, William P

Mayo Clinic

No container title available | January 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.60191.sa2 Get It

MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor–1
Popay, Tessa M. , Howard, Gregory C. , Codreanu, Simona G. , Sherrod, Stacy D. , McLean, John A. , Thomas, Lance R. , Lorey, Shelly L. , Machida, Yuichi , Weissmiller, April M. , Eischen, Christine M. , Sherrod, Stacy D , Machida, Yuichi J, Eischen, Christine M , Tansey, William P , Wang, Jing , Adams, Clare M. , Liu, Qi

Mayo Clinic

eLife | January 8, 2021 | Volume: 10 | Issue: No issue available | Pages: No page available

10.7554/elife.60191 | PMID 33416496 Get It

The oncoprotein transcription factor MYC is a major driver of malignancy and a highly validated but challenging target for the development of anticancer therapies. Novel strategies to inhibit MYC may come from understanding the co-factors it uses to drive pro-tumorigenic gene expression programs, providing their role in MYC activity is understood. Here we interrogate how one MYC co-factor, host cell factor (HCF)–1, contributes to MYC activity in a human Burkitt lymphoma setting. We identify genes connected to mitochondrial function and ribosome biogenesis as direct MYC/HCF-1 targets and demonstrate how modulation of the MYC–HCF-1 interaction influences cell growth, metabolite profiles, global gene expression patterns, and tumor growth in vivo. This work defines HCF-1 as a critical MYC co-factor, places the MYC–HCF-1 interaction in biological context, and highlights HCF-1 as a focal point for development of novel anti-MYC therapies.
USP24 Is a Cancer-Associated Ubiquitin Hydrolase, Novel Tumor Suppressor, and Chromosome Instability Gene Deleted in Neuroblastoma
Zhang, Ying , Ali, Asma, Jeon, Young Jin , Galardy, Paul J. , Bedekovics, Tibor , Jeon, Young J, Hussain, Sajjad

Mayo Clinic

Cancer Research | December 22, 2020 | Volume: 81 | Issue: 5 | Pages: 1321-1331

10.1158/0008-5472.can-20-1777 | PMID 33355202 Get It

Abstract Deubiquitinating enzymes are increasingly recognized to play important roles in cancer, with many acting as oncogenes or tumor suppressors. In this study, we employed a bioinformatics approach to screen for enzymes from this family involved in cancer and found USP24 as a potent predictor of poor outcomes in neuroblastoma, an aggressive childhood cancer. USP24 resides in a region commonly deleted in neuroblastoma, yet was independently associated with poor outcomes in this disease. Deletion of Usp24 in a murine model resulted in degradation of collapsin response mediator protein 2 (CRMP2), a regulator of axon growth, guidance, and neuronal polarity. Cells lacking USP24 had significant increases in spindle defects, chromosome missegregation, and aneuploidy, phenotypes that were rescued by the restoration of CRMP2. USP24 prevented aneuploidy by maintaining spindle-associated CRMP2, which is required for mitotic accuracy. Our findings further indicate that USP24 is a tumor suppressor that may play an important role in the pathogenesis of neuroblastoma. Significance: This study identifies the chromosome instability gene USP24 as frequently deleted in neuroblastoma and provides important insight into the pathogenesis of this aggressive childhood cancer.
Investigating gene expression changes underlying selective hippocampal vulnerability in Alzheimer’s disease using a translational neuropathology approach
Crist, Angela M. , Hinkle, Kelly M., Wang, Xue , Lesser, Elizabeth R. , Azu, Nkem O. , Frankenhauser, Isabelle , Liesinger, Amanda M., Serie, Daniel, DeTure, Michael , Cook, Casey , Petrucelli, Leonard , Petersen, Ronald C. , Duara, Ranjan , Graff‐Radford, Neill R. , Allen, Mariet , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Asmann, Yan W. , Moloney, Christina M. , Labuzan, Sydney A. , Matchett, Billie J. , Duara, Ranjan , Carrasquillo, Minerva M. , Li, Hu, Ross, Owen A. , Dickson, Dennis W. , Carter, Rickey E. , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S2 | Pages: No page available

10.1002/alz.041199 Get It

AbstractBackgroundUsing an objective mathematical algorithm to assess corticolimbic involvement of neurofibrillary tangle pathology, we identified three AD subtypes: hippocampal sparing (HpSp) AD, typical AD, and limbic predominant AD. Typical AD brains were representative of the expected patterns of hippocampal and cortical involvement as outlined by Braak tangle stage. In contrast, we discovered an extreme phenotype that exists outside of the Braakian‐concept of neurofibrillary tangle patterns. Hippocampal sparing AD cases demonstrate unexpected sparing of the hippocampus relative to severely involved association cortices and limbic predominant AD cases demonstrate inundation of the hippocampus relative to mildly involved association cortices. Using these AD subtypes, our objective was to leverage our understanding of disease spectrum to uncover transcriptomic changes that underlie selective vulnerability of the hippocampus in AD.MethodWe performed RNA‐sequencing in 40 neuropathologically diagnosed AD cases (10 HpSp, 20 Typical and 10 Limbic) and 15 controls to uncover gene expression changes associated with phenotype differences allowing us to prioritize 44 genes for further exploration. Validation with NanoString and quantification with digital pathology were performed in an expanded cohort of 158 AD cases (36 HpSp, 79 Typical and 35 Limbic) and 32 controls. We quantified digital pathology measures of early tangle pathology (CP13), mature tangle pathology (Ab39), amyloid‐β (33.1.1). In addition, we measured cellular markers for microglia (CD68), endothelia (CD34), and astroglia (GFAP). Deep learning based prediction models were employed, which nominated the SLC38A2 gene as a predictor of AD.ResultThe SLC38A2 gene was originally prioritized in our RNA‐sequencing data based upon differential expression between controls and typical AD. We observed upregulation of SLC38A2 in all AD subtypes. RNA‐seq gene expression measures validated well with NanoString for SLC38A2 (R=0.97, p<0.001). Regression analysis identified early tangle (p=0.011) and late tangle measures (p=0.026) as significant predictors of gene expression, but not amyloid measures (p=0.74). Microgliosis approached significance (p=0.052), but with no contribution from endothelial cell burden (p=0.17) or astrogliosis (p=0.58). Age approached significance (p=0.06), but not sex (p=0.88) or APOE‐ε4 status (p=0.10).ConclusionOur data supports consideration of intra‐disease divergence with regard to case stratification and may reveal genes previously masked by heterogeneity of cohorts.
Deploying MMEJ using MENdel in precision gene editing applications for gene therapy and functional genomics
Martínez‐Gálvez, Gabriel , Joshi, Parnal , Friedberg, Iddo , Ekker, Stephen C. , Ekker, Stephen C , Manduca, Armando

Mayo Clinic

Nucleic Acids Research | November 24, 2020 | Volume: 49 | Issue: 1 | Pages: 67-78

10.1093/nar/gkaa1156 | PMID 33305328 Get It

Abstract Gene-editing experiments commonly elicit the error-prone non-homologous end joining for DNA double-strand break (DSB) repair. Microhomology-mediated end joining (MMEJ) can generate more predictable outcomes for functional genomic and somatic therapeutic applications. We compared three DSB repair prediction algorithms – MENTHU, inDelphi, and Lindel – in identifying MMEJ-repaired, homogeneous genotypes (PreMAs) in an independent dataset of 5,885 distinct Cas9-mediated mouse embryonic stem cell DSB repair events. MENTHU correctly identified 46% of all PreMAs available, a ∼2- and ∼60-fold sensitivity increase compared to inDelphi and Lindel, respectively. In contrast, only Lindel correctly predicted predominant single-base insertions. We report the new algorithm MENdel, a combination of MENTHU and Lindel, that achieves the most predictive coverage of homogeneous out-of-frame mutations in this large dataset. We then estimated the frequency of Cas9-targetable homogeneous frameshift-inducing DSBs in vertebrate coding regions for gene discovery using MENdel. 47 out of 54 genes (87%) contained at least one early frameshift-inducing DSB and 49 out of 54 (91%) did so when also considering Cas12a-mediated deletions. We suggest that the use of MENdel helps researchers use MMEJ at scale for reverse genetics screenings and with sufficient intra-gene density rates to be viable for nearly all loss-of-function based gene editing therapeutic applications.
Epidural Stimulation Combined with Triple Gene Therapy for Spinal Cord Injury Treatment
Исламов, Р. Р. , Bashirov, F. V , Fadeev, Filip , Shevchenko, Roman , Izmailov, Andrei , Markosyan, Vage , Sokolov, Mikhail , Kuznetsov, Maksim , Davleeva, Maria, Garifulin, Ravil , Салафутдинов, И. И. , Нуруллин, Л. Ф. , Chelyshev, Y. A., Lavrov, Igor , Islamov, Rustem , Salafutdinov, Ilnur , Nurullin, Leniz , Lavrov, Igor

Mayo Clinic

International Journal of Molecular Sciences | November 24, 2020 | Volume: 21 | Issue: 23 | Pages: 8896

10.3390/ijms21238896 | PMID 33255323 Get It

The translation of new therapies for spinal cord injury to clinical trials can be facilitated with large animal models close in morpho-physiological scale to humans. Here, we report functional restoration and morphological reorganization after spinal contusion in pigs, following a combined treatment of locomotor training facilitated with epidural electrical stimulation (EES) and cell-mediated triple gene therapy with umbilical cord blood mononuclear cells overexpressing recombinant vascular endothelial growth factor, glial-derived neurotrophic factor, and neural cell adhesion molecule. Preliminary results obtained on a small sample of pigs 2 months after spinal contusion revealed the difference in post-traumatic spinal cord outcomes in control and treated animals. In treated pigs, motor performance was enabled by EES and the corresponding morpho-functional changes in hind limb skeletal muscles were accompanied by the reorganization of the glial cell, the reaction of stress cell, and synaptic proteins. Our data demonstrate effects of combined EES-facilitated motor training and cell-mediated triple gene therapy after spinal contusion in large animals, informing a background for further animal studies and clinical translation.